drugset
drugset / Trial / NCT04701060

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

NCT04701060 ↗

Phase 2 Completed 31 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence

Timeline

Start
2021-01-26
Primary completion
2024-03-04
Completion
2024-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Rivoceranib Small molecule 250 mg Oral

Indications

hepatocellular carcinoma